Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals PLC

Annual Report and Accounts for the year ended 30 June 2012

Our Business

Our Strategy

  • To develop an international high growth, cash generative, specialist veterinary products business; and
  • To sustain growth and innovate in our Services business

Our Highlights

  • €135 million acquisition of Eurovet® Animal Health B.V. ("Eurovet") completed, funded by successful Rights Issue and debt re-financing
  • Strong performance from Pharmaceuticals in both Europe and the USA
  • NVS operating margin stabilised in second half
  • Investment in product pipeline increased by 10%
  • Strong second half cash inflow resulted in a 92% full year conversion rate

Our Key Strengths

  • ­Unique Products
  • People and Expertise
  • Strategic Focus
  • International Footprint
  • Strong Financial Platform
  • Development Pipeline
  • Strong Market Position
  • Growing Markets
  • Customer Satisfaction
  • Innovation

We use cookies and track users anonymously, check this box and save to disable. We are inferring consent by continuing.